Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

• Status: Terminated
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alberta Health Services
• Collaborator: Canadian Institutes of Health Research (CIHR)
• Treatments: Haloperidol; Haloperidol decanoate; Olanzapine

Criteria

Inclusion Criteria:

• >18 years of age

• Significant nausea/vomiting

• Failed maxeran and domperidone

• Underlying treatment of causes has failed

• Adequate cognitive function

• Communicates well

Exclusion Criteria:

• Partial/complete bowel obstruction

• Currently taking Haldol or olanzapine

• Has drug induced extrapyramidal symptoms

• Parkinson's disease

• Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus